fbpx

Day

December 11, 2012
  Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed the first European patient in its ongoing international Phase 2b clinical trial of MYDICAR, Celladon's first in class therapeutic for the treatment of advanced heart failure (HF). The Phase 2b study...

News

The Lundbeck Foundation increases its commitment to IO Biotech
12. January 2021
The Lundbeck Foundation launches 2030 strategy with ambitious goals for grant and commercial activities
22. December 2020
Lundbeck foundation awards grants worth dkk 57 million to bold projects
15. December 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge